Finnish DelSiTech and Swiss-based Optifye Therapeutics have announced an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech Silica Matrix technology.
Controlled release of dexamethasone eye drops, based on DelSiTech Silica Matrix technology, is an eye drop product that is applied as a single drop, once daily under the eye lid which maintains therapeutic drug concentration in the eye for the entirety of the day, removing the need for repeat applications, states the company.
“We are excited to be collaborating with the team at Optifye to bring innovative eye drop solutions to patients. The continued validation of our technologies inspires us now more than ever to push beyond development and into commercialization. We value partners such as Optifye, not only for their guiding expertise in ophthalmology, but for their role in DelSiTech’s ongoing advancement towards becoming a commercial pharmaceutical company with an important presence in the ophthalmic sector,” says Lasse Leino, CEO of DelSiTech.